{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"description":"Number of participants with anti-CZP antibodies were reported.","groups":[{"description":"Participants received reduced CZP sc as a fixed dose based on their body weight Q2W or Q4W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.","id":"OG000","title":"Reduced CZP Dose"},{"description":"Participants received original CZP sc as a fixed dose based on their body weight Q2W throughout the study. Participants started with 3 loading doses of CZP at Weeks 0, 2, and 4 followed by a maintenance dose for the duration of the study.","id":"OG001","title":"Original CZP Dose"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Set (SS) consisted of all study participants in the Enrolled Set (ES) who have received at least 1 dose of study medication. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 48","title":"Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48","type":"PRIMARY","unitOfMeasure":"Participants"}